Core Insights - Protalix BioTherapeutics reported a record revenue of $53.0 million for the fiscal year 2024, marking a 31% increase from $40.4 million in 2023, driven by sales growth across all revenue streams [5][9] - The company successfully completed a First-in-Human study for its gout candidate PRX-115, with plans to initiate a Phase II clinical trial in the second half of 2025 [2][6] - Protalix has strengthened its balance sheet by fully repaying its debt and eliminating outstanding warrants, positioning itself for future growth [2][7] Financial Highlights - Total revenue for 2024 was $53.4 million, a decrease from $65.5 million in 2023, primarily due to a significant drop in revenues from license and R&D services, which fell to $0.4 million from $25.1 million [9][19] - Cost of goods sold increased by 6% to $24.3 million in 2024, compared to $23.0 million in 2023, attributed mainly to higher sales to Chiesi [9] - Research and development expenses decreased by 24% to approximately $13.0 million in 2024, down from $17.1 million in 2023, due to the completion of the Fabry clinical program [9][19] Clinical Developments - The European Medicines Agency validated a variation submission for pegunigalsidase alfa, allowing for a less frequent dosing regimen for Fabry disease patients [4] - Protalix's pipeline includes PRX-115 for uncontrolled gout and PRX-119 for NETs-related diseases, with ongoing evaluations for further development [2][14] Corporate Developments - The company repaid all outstanding principal and interest on its 7.50% Senior Secured Convertible Promissory Notes in September 2024, financed entirely with available cash [7] - Protalix's cash and cash equivalents stood at approximately $34.8 million as of December 31, 2024, with a net income of approximately $2.9 million for the year [9][19]

Pluxee announces the launch of its first commercial paper program (NEU CP) for up to 400 million euros Issy-les-Moulineaux, March 12, 2025 // Pluxee (the “Group”) announces the launch of its first program for the issuance of Negotiable European Commercial Paper (NEU CP) with a limit of up to 400 million euros. Pluxee will benefit from a flexible and cost-effective short-term funding solution while expanding the available options to support its financial strategy. This program, primarily denominated in euros ...

Regulated information Paris, March 3, 2025 DECLARATION OF TRANSACTIONS IN OWN SHARES N° 2025/03 Period of: From February 24 to February 28, 2025 Issuer: Pluxee N.V. Class of Securities: Ordinary shares (ISIN NL0015001W49) Aggregate presentation by day and by market Issuer CodeTransaction dateISIN CodeDaily total volume (in number of shares)Daily weighted average price of shares acquiredPlatform213800RQNIQT48SEEO8524-Feb-25NL0015001W4919 08021,9240XPAR213800RQNIQT48SEEO8524-Feb-25NL0015001W49<td style="bord ...

Company Overview - Pluxee is a global player in Employee Benefits and Engagement, operating in 29 countries [2] - The company offers a broad range of solutions across Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [2] - Pluxee has over 5,400 engaged team members and serves more than 500,000 clients, 37 million+ consumers, and 1.7 million+ merchants [2] - The company has been conducting business for more than 45 years and is committed to creating a positive impact on local communities and supporting employee well-being [2] Share Transactions - From February 17 to February 21, 2025, Pluxee conducted multiple transactions in its own shares [1] - On February 17, 2025, the total volume of shares acquired was 36,930 across three platforms, with average prices ranging from €23.0452 to €23.3239 [1] - On February 18, 2025, the total volume was 37,436 shares, with average prices between €22.7215 and €22.8028 [1] - On February 19, 2025, the total volume was 40,403 shares, with average prices from €22.1382 to €22.1716 [1] - On February 20, 2025, the total volume was 40,195 shares, with average prices between €21.8400 and €21.8466 [1] - On February 21, 2025, the total volume was 42,000 shares, with average prices ranging from €21.8966 to €21.9388 [1]

Core Viewpoint - Protalix Biotherapeutics Inc is gaining attention for its focus on rare diseases and innovative treatments, with analysts suggesting it is on the verge of sustainable profitability [1][10]. Revenue Growth - The company's flagship drug, Elfabrio, is driving revenue growth, particularly as a treatment for Fabry disease, a rare genetic disorder [2][3]. - Elfabrio is gaining traction globally through commercialization partner Chiesi Global Rare Diseases, with analysts projecting sustainable profitability primarily from Elfabrio's royalty stream [3][10]. Competitive Advantages - Elfabrio offers competitive advantages over existing treatments, including a longer presence in the bloodstream and reduced immune response [4]. Established Treatments - Protalix also has a significant presence in treating Gaucher disease with its drug Elelyso, which maintains a 25% market share in Brazil [5]. Unique Production Platform - The company's proprietary ProCellEx platform allows for the production of biologic drugs using plant cells, offering a simplified manufacturing process and natural viral resistance [6][7]. Pipeline Expansion - Protalix is advancing PRX-115, a drug designed to treat uncontrolled gout, with promising Phase 1 results and a Phase 2 trial expected in the second half of 2025 [8][10]. Financial Position - The company has improved its financial position by eliminating $65 million in debt over the last five years and holding over $27 million in cash as of September 30, 2024 [9][10]. Future Growth Potential - Analysts believe Protalix's revenue streams and drug pipeline position it for substantial upside, with potential exponential increases in value if PRX-115's Phase 2 results are favorable [10][11]. Research and Development - Protalix is exploring early-stage research into rare renal diseases and additional lysosomal disorders, targeting therapies that address unmet medical needs [11][12]. Market Position - Protalix has demonstrated its ability to develop and commercialize treatments for rare diseases, a notable achievement for small-cap biotech firms [13][14].

Group 1 - Pluxee N.V. disclosed transactions on treasury shares from February 11 to February 14, 2025, detailing daily volumes and average prices [1] - The total number of shares acquired on February 11 was 21,549 shares at an average price of €22.55 [1] - On February 12, a total of 33,925 shares were acquired at an average price of €22.41 [1] - The transactions on February 13 totaled 33,140 shares at an average price of €22.60 [1] - On February 14, 35,660 shares were acquired at an average price of €22.77 [1] Group 2 - Pluxee operates in 29 countries, focusing on Employee Benefits and Engagement, with a client base of over 500,000 and more than 37 million consumers [2] - The company has been in business for over 45 years and employs more than 5,400 team members [2] - Pluxee's solutions include Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits, aimed at attracting and retaining talent [2]

Core Viewpoint - Pluxee has announced a share buy-back program of up to 15 million euros to support its performance share allocation plan, effective from February 11, 2025, until May 30, 2025 [1][2]. Group 1: Share Buy-Back Program - The share buy-back program will be executed in compliance with the authorization from the General meeting of shareholders and relevant market regulations [1][2]. - The shares repurchased will be held as treasury stock solely to fulfill the company's obligations under its performance share plan [2]. Group 2: Company Overview - Pluxee operates globally in the Employee Benefits and Engagement sector across 29 countries, providing solutions in Meal & Food, Well-being, Lifestyle, Reward & Recognition, and Public Benefits [3]. - The company has over 5,400 engaged team members and serves more than 500,000 clients, 37 million consumers, and 1.7 million merchants [3]. - With over 45 years of experience, Pluxee is dedicated to positively impacting local communities and promoting employee well-being while also focusing on environmental protection [3].

Group 1 - Proactive specializes in providing fast, accessible, informative, and actionable business and finance news content to a global investment audience [2][3] - The company focuses on medium and small-cap markets while also covering blue-chip companies, commodities, and broader investment stories [3] - Proactive's news team delivers insights across various sectors including biotech, pharma, mining, natural resources, battery metals, oil and gas, crypto, and emerging technologies [3] Group 2 - Proactive has a strong emphasis on technology adoption, utilizing both human expertise and technological tools to enhance workflows [4] - The company employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]

Company Overview - Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system [4] - The company is notable for being the first to receive FDA approval for a protein produced through a plant cell-based suspension expression system [4] - Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa, its first product, to Pfizer Inc., while retaining full rights in Brazil [4] Recent Developments - Protalix will present at the 2025 BIO CEO & Investor Conference on February 11, 2025, at 10:15 AM EST [1][2] - The company’s second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023 [4] - Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio [5] Product Pipeline - Protalix's development pipeline includes proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets, such as: - PRX–115: a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout [5] - PRX–119: a plant cell-expressed long-action DNase I for NETs-related diseases [5]

Company Overview - Pluxee is a global leader in Employee Benefits and Engagement, operating in 29 countries with a focus on Meal & Food, Wellbeing, Lifestyle, Reward & Recognition, and Public Benefits [2] - The company serves over 500,000 clients, 37 million+ consumers, and 1.7 million+ merchants, supported by more than 5,000 team members and advanced technology [2] - Pluxee has been in business for over 45 years, emphasizing positive community impact, employee wellbeing, and environmental sustainability [2] Liquidity Contract Summary - As of December 31, 2024, the liquidity account held 200,439 Pluxee N.V. ordinary shares valued at €5,878,911 [4] - During the period from July 1, 2024, to December 31, 2024, the company purchased 972,323 ordinary shares worth €19,626,472 across 6,377 transactions and disposed of 848,300 ordinary shares worth €17,195,841 across 5,661 transactions [4] - In the previous half-yearly report as of June 30, 2024, the liquidity account held 59,130 Pluxee N.V. ordinary shares valued at €8,621,644 [4] - From January 31, 2024, to June 30, 2024, the company purchased 723,308 ordinary shares worth €19,930,588 across 5,132 transactions and disposed of 719,315 ordinary shares worth €19,933,554 across 4,627 transactions [4] - The liquidity account started with €10,000,000 as of January 31, 2024 [4]